Simeprevir once a day with peginterferon alfa-@a and ribavirin was well tolerated in HCV genotype @-infected previous non-responders and was non-inferior to telaprevir , thus providing an alternative treatment in areas of the world where all-oral HCV regimens are not available or accessible .